Who has invested in Lyell Immunopharma?

GlaxoSmithKline, Celgene are named among the investors backing Lyell Immunopharma.

Lyell Immunopharma Funding: $493M Raised, IPO (2023)

Lyell Immunopharma funding overview

Lyell Immunopharma is based in Seattle. Lyell Immunopharma has raised $493M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in August 2023. The round record for Lyell Immunopharma runs through 2023; nothing later has been disclosed. Investors on record include GlaxoSmithKline, Celgene. 2 distinct backers are named across the disclosed rounds.

Lyell Immunopharma at a glance

Total raised: $493M
Latest round: IPO
Latest round date: August 2023
Headquarters: Seattle
Notable investors: GlaxoSmithKline, Celgene

Frequently asked about Lyell Immunopharma funding

How much has Lyell Immunopharma raised?: Lyell Immunopharma has raised $493M in total disclosed funding across the rounds on record.
Who has invested in Lyell Immunopharma?: GlaxoSmithKline, Celgene are named among the investors backing Lyell Immunopharma.
What was the latest Lyell Immunopharma funding round?: The most recent disclosed round is an IPO, announced in August 2023.
Where is Lyell Immunopharma based?: Lyell Immunopharma is based in Seattle.
When did Lyell Immunopharma last raise?: The last disclosed Lyell Immunopharma round closed in August 2023 at IPO.

Round data for Lyell Immunopharma is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Seattle and backer lists below.

Lyell Immunopharma Funding: $493M Raised, IPO (2023)

Lyell Immunopharma funding overview

Lyell Immunopharma at a glance

Frequently asked about Lyell Immunopharma funding

Companies related to Lyell Immunopharma (18)

Browse related funding lists (5)